preclinical data
-
Wave Life Sciences Presents Preclinical WVE-007 Obesity Data at ObesityWeek® 2025
Wave Life Sciences will present preclinical data for WVE-007 (INHBE GalNAc-siRNA) at ObesityWeek, showcasing its potential to drive fat loss while preserving muscle with infrequent dosing. Preclinical studies in DIO mice demonstrated significant weight loss, reduced visceral fat, and improved insulin sensitivity. When combined with semaglutide, weight loss doubled. Early clinical data from the INLIGHT trial show dose-dependent Activin E reductions (56-85%) that were sustained through six months. WVE-007 has shown a promising safety profile.
-
BBO-10203, a Novel RAS:PI3Kα Inhibitor, Demonstrates Promising Preclinical Efficacy in KRAS-Mutant Tumors without Hyperglycemia: Data Presented at AACR-NCI-EORTC 2025
BridgeBio Oncology Therapeutics announced positive preclinical data for BBO-10203, a novel compound selectively disrupting the RAS:PI3Kα interaction crucial for KRAS-mutant tumor growth. BBO-10203 inhibits RAS-driven PI3Kα-AKT signaling without causing hyperglycemia. In vivo studies showed oral bioavailability and significant anti-tumor activity, with deep tumor regressions when combined with BridgeBio’s KRAS inhibitors. BBO-10203 is currently in Phase 1 trial (BREAKER-101), and initial Phase 1 clinical data is expected in H1 2026.
-
Cullinan Therapeutics Presents Preclinical Data on CLN-978 B Cell Depletion at ACR Convergence 2025, Supporting Clinical Development in Autoimmune Diseases
Cullinan Therapeutics will present preclinical data on CLN-978, a CD19xCD3 bispecific T cell engager, at ACR Convergence 2025. Studies show CLN-978 rapidly depleted B cells in samples from RA, Sjögren’s, and SLE patients, and in nonhuman primates after subcutaneous dosing. In a SLE mouse model, it reduced B cells, anti-dsDNA IgG, and kidney IgG deposition. Cullinan is advancing CLN-978 in OUTRACE clinical programs for RA, SjD, and SLE.
-
MP0726: Preclinical Data on Mesothelin-Targeting Radio-DARPin Presented by Molecular Partners and Orano Med at SNMMI 2025
Molecular Partners, in collaboration with Orano Med, is advancing its Radio-DARPin candidate, MP0726, which targets mesothelin (MSLN) for ovarian cancer treatment. Preclinical data reveals promising tumor accumulation and favorable biodistribution, including a high tumor-to-kidney ratio. The program leverages Molecular Partners’ Radio-DARPin platform, designed to improve the delivery of radioactive payloads to solid tumors. MP0726’s preclinical data is to be presented at the 2025 SNMMI Annual Meeting.
